Consistency evaluation of this pharmaceutical company has been harvested again and again, and 2 varieties have been evaluated within a month

Tianyao announced on the evening of March 22 that its subsidiary Jinyao Pharmaceutical's Dexamethasone Sodium Phosphate Injection passed the quality and efficacy consistency evaluation of generic drugs
.
Dexamethasone Sodium Phosphate Injection is mainly used for allergic and autoimmune inflammatory diseases, mostly for connective tissue disease, active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, ulcerative colon It is also used for the comprehensive treatment of some serious infections, poisoning, and malignant lymphoma
.
According to Minenet data, the sales of dexamethasone sodium phosphate injection in urban public hospitals, county-level public hospitals, urban community hospitals, and township health centers in 2020 will be about 229 million yuan, and the sales in the first half of 2021 will be about 135 million yuan
.
At present, more than 100 domestic companies have been approved for listing of Dexamethasone Sodium Phosphate Injection, but only three companies, including Tianyao, have passed the consistency evaluation
.
The drug under Tianyao has a strong competitive advantage in the domestic market
.
It is worth mentioning that, in addition to Dexamethasone Sodium Phosphate Injection, Tianyao's preparation business has made progress in consistency evaluation since March
.
On March 11, Tianyao announced that its subsidiary Tianjin Jinyao Pharmaceutical Co.
, Ltd.
's metahydroxyamine bitartrate injection had passed the quality and efficacy consistency evaluation of generic drugs
.
It is reported that the product is suitable for the prevention and treatment of acute hypotension during spinal anesthesia
.
At present, there are 11 companies in the domestic market that have approved the marketing of metahydroxylamine bitartrate injection, among which Jinyao Pharmaceutical is the first company that has been reviewed for this product
.
According to the data of Minet.
com, the national sales of metahydroxyamine bitartrate injection in 2020 will be about 524 million yuan, and the sales in the first half of 2021 will be about 361 million yuan
.
In addition, on March 1, Tianyao announced that its subsidiary Hubei Tianyao received the "Drug Registration Certificate" for Compound Amino Acid Injection (17AA-II) approved and issued by the State Food and Drug Administration
.
It means that the drug has the qualification for domestic production and sales
.
It is understood that compound amino acid injection (17AA-II) is mainly used for patients with acute and chronic renal insufficiency in hypoalbuminemia, low nutritional status and amino acid supplementation before and after surgery
.
In recent years, the sales of such drugs in the domestic market have shown an increasing trend
.
According to the data from Minet.
com, the domestic sales of similar drugs with the same dosage form, prescription content, efficacy and dosage in 2019 and 2020 were 123 million yuan and 308 million yuan respectively
.
According to the data, Tianyao Co.
, Ltd.
, formerly known as Tianjin Pharmaceutical Factory, has a history of more than 80 years.
It is one of the earliest companies in China to develop and produce corticosteroid APIs.
It has been committed to scientific and technological innovation and large-scale production for many years
.
In 2017, the company began to build a whole industry chain layout of "APIs + preparations" centered on steroid hormones and amino acids.
Subsequently, the preparation business segment developed rapidly, and its revenue has accounted for half of the country
.
According to the third quarterly report of Tianyao in 2021, the company's main income was 2.
653 billion yuan, a year-on-year increase of 12.
08%; the net profit attributable to the parent was 53.
3246 million yuan, a year-on-year decrease of 45.
07%
.
The industry believes that with the over-evaluation of multiple varieties of the pharmaceutical company and the approval of new products for listing, it will help to enhance the company's competitiveness and will have a positive impact on the improvement of Tianyao's future performance
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.